Central Nervous System (CNS) diseases affect approximately 20% of the world population. At the same time CNS treatment development is the riskiest business of all pharmaceutical domains. Electroencephalography (EEG) yields cost-effective, direct, and non-invasive measures of brain activity. We envision the combination of EEG with AI approaches to offer a solution for efficient CNS treatment development. We have developed an EEG-based brain test that provides objective physiological markers. This tool can be used for informed recruitment in clinical trials to select those patients at the disease earliest stage and therefore with the largest probability of treatment efficacy.